Immunotherapy With Lupus or Scleroderma — Is It Ever Possible?

Sometimes yes, with more caution than for most autoimmune conditions. Lupus and scleroderma are not absolute contraindications in current guidance. They are higher-risk situations, judged on how active your disease is and which organs it already involves. The decision is made case by case, by your oncologist together with your rheumatologist.

That is rarely what patients are told. Most people living with a connective tissue disease hear something much shorter — that immunotherapy is “risky”, or “not for you” — without being told which part of their disease is the problem, or what would change the answer. An unexplained no is not the same thing as an assessed one, and this page exists to close that gap.

The caution itself is real, and it is worth understanding why. Lupus and systemic sclerosis behave differently from the autoimmune conditions eligibility discussions are usually built around. They are multi-system. They can already have damaged the kidney or the lung before cancer entered the picture. And the immune-related side effects of immunotherapy tend to land on exactly those organs. That overlap, not the name of your diagnosis, is what drives the extra care.

This page is general patient education. It cannot tell you whether immunotherapy is safe for you. That assessment needs your diagnosis, your current disease activity, your medicines, your organ function and your scans in front of a medical oncologist working with the specialist who manages your connective tissue disease.

Yes, in selected patients. Neither condition is listed as an absolute bar in ASCO, ESMO or NCCN guidance on immune-related toxicity. What decides it is disease activity, how much immunosuppression you need, and how much kidney and lung reserve you have left. Quiet disease with intact organ function is a very different conversation from active disease.

Two separate risks get muddled constantly, and it helps to keep them apart. The first is a flare of the disease you already have. The second is a new immune-related side effect in an organ your disease has never touched — a thyroid, liver, bowel, lung or skin reaction that any patient on immunotherapy can develop. Having lupus or scleroderma raises the first risk. It does not exempt you from the second.

In scleroderma the specific concern is usually the lung. Many patients already have interstitial lung disease and reduced reserve. Immunotherapy can cause pneumonitis, an inflammation of the lung tissue. On a lung that is already scarred there is less margin before symptoms appear, and new inflammation is harder to tell apart from old scarring on a scan. That is why a baseline lung assessment carries more weight here than in almost any other eligibility discussion. Pulmonary hypertension, swallowing difficulty from oesophageal involvement and blood pressure control are weighed at the same time.

In lupus the specific concern is usually the kidney, together with the amount of immunosuppression needed to keep the disease quiet. Lupus nephritis leaves less kidney reserve, and immunotherapy can cause its own kidney inflammation. A high baseline steroid or disease-modifying dose also pulls against what immunotherapy is trying to do. Lupus that has involved the nervous system or the blood counts is weighed separately again, with the relevant specialist involved.

Be careful with numbers on this topic. Patients with lupus and systemic sclerosis were excluded from the trials that led to approval, and they remain a small minority in the retrospective series published since. Anyone quoting you a confident percentage for your own disease is going beyond the evidence that exists.

General patterns at guidance level only. Your own team’s assessment of your case overrides anything in this table, in either direction. If your autoimmune condition also affects the nervous system, Immunotherapy With Myasthenia Gravis or Neurological Autoimmunity covers that group in more detail.

Higher than for someone without a connective tissue disease, and less predictable. Published series report flares in a substantial minority of patients with pre-existing autoimmune disease. The figures for lupus and systemic sclerosis specifically are too few and too varied to quote. Most reported flares were managed by holding treatment and treating the flare.

Timing follows a rough pattern. A flare of your existing disease tends to appear in the first weeks to few months. A new immune-related side effect can appear at any point, including weeks or months after treatment finishes. Both are why your monitoring schedule is tighter than the standard one.

The harder problem with these two diseases is telling things apart. Joint pain, fatigue, breathlessness, a rash, skin that feels tighter, Raynaud’s symptoms — each of these can be your disease, or the treatment, or both at once. A short written record of what your disease normally does to you, made before you start, is one of the most useful things you can hand your oncology team. It turns “is this new?” from a guess into a comparison.

What makes the practical difference is not the flare itself. It is how quickly it is recognised. Stiffness you would normally sit out for a fortnight is worth reporting the same week once you are on immunotherapy, because the team needs to know whether it is your disease or something new before it grows.

Some symptoms should not wait for a scheduled review at all. New or worsening breathlessness, a dry cough that is getting worse, chest pain, severe or bloody diarrhoea, a sharp fall in urine output or new swelling, a sudden rise in blood pressure, yellowing of the eyes or skin, or new muscle weakness: contact your oncology team the same day, and go to the emergency department now if it is severe or getting worse. Do not manage these at home and do not wait for the next cycle. If you cannot reach your treating doctor, call 1800 202 8726.

Whether the cancer is responding is assessed separately from safety, on a planned schedule your oncologist sets. Response-assessment PET-CT is coordinated at partner imaging centres rather than performed at CION.

• Your current medicine list with doses — steroids, disease-modifying drugs and biologics. The dose matters as much as the name.
• Your rheumatologist’s most recent letter — usually the quickest evidence of how active your disease is right now.
• Recent kidney results — creatinine and a urine protein test, plus a note of what your blood pressure normally runs at.
• Lung reports, if scleroderma has involved your lungs — the last breathing test and the last chest scan report.
• A short flare history — how often, how bad, what settled it, and when the last one was. Two lines is enough.
• Your rheumatologist’s contact details — so the two teams can speak directly instead of relaying messages through you.

• For the wider picture across every autoimmune condition, Can You Have Immunotherapy With an Autoimmune Disease? is the page this one sits under.
• If your disease also affects the nerves or muscles, Immunotherapy With Myasthenia Gravis or Neurological Autoimmunity covers that higher-caution group.
• If you want the genuine contraindications set out honestly, Who Should Not Have Immunotherapy at All? covers who this treatment is not for.
• For how immunotherapy is delivered, monitored and followed up as day care, see Immunotherapy at CION Cancer Clinics.

General patient-education information only. Nothing here states or implies that immunotherapy is safe, suitable or unsuitable for you — that assessment is made by your treating medical oncologist together with the rheumatologist who manages your lupus or scleroderma. Response-assessment PET-CT is coordinated at partner imaging centres.

Get the Eligibility Question Answered Properly

A medical oncologist, working with the specialist who manages your lupus or scleroderma, can tell you where you actually stand — and what the monitoring plan would look like.

This page is general patient-education information, not a substitute for the written assessment your own oncology and rheumatology teams give you for your specific case.